Biobohemia
Biotechnology, 1 Broadway, Cambridge, , 2142, Massachusetts, United States, 1-10 Employees
Who is BIOBOHEMIA
Biobohemia, Inc. is a biotechnology company focused on development of cancer vaccines. Biobohemia's lead technology is cell Antigenic Essence production via proteomics and cell culture te...
Read More
- Headquarters: 1 Broadway, Cambridge, Massachusetts, 2142, United States
- Date Founded: 2019
- Employees: 1-10
- Revenue: Under $1 Million
- Active Tech Stack: See technologies
- CEO: Mikhael Goldsblat
Industry: Biotechnology
Does something look wrong? Fix it. | View contact records from BIOBOHEMIA
Biobohemia Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Biobohemia
Answer: Biobohemia's headquarters are located at 1 Broadway, Cambridge, , 2142, Massachusetts, United States
Answer: Biobohemia's official website is https://biobohemia.com
Answer: Biobohemia's revenue is Under $1 Million
Answer: Biobohemia has 1-10 employees
Answer: Biobohemia is in Biotechnology
Answer: Biobohemia contact info: Phone number: Website: https://biobohemia.com
Answer: Biobohemia, Inc. is a biotechnology company focused on development of cancer vaccines. Biobohemia's lead technology is cell Antigenic Essence production via proteomics and cell culture technology, and which is a deep upgrade of cellular cancer vaccines. Cellular cancer vaccines are among the first types of cancer vaccines to be tested. They use a straightforward approach based on the well-known principle of vaccination vaccinate with what you want to develop protection against. The significant possibilities of such vaccines have been described, but none have yet passed the clinical trial stage. Antigenic essence technology is the revitalization of cellular vaccination, as antigenic essence exhibits all the identifying properties of cancer cells while also allowing for control of composition, purification from ballast substances (cellular 'noise'), and evasion of MHC restrictions. Therefore, antigenic essence technology allows upgrading of already discovered cellular compositions, as well as creation new ones. Our antigenic essence technology platform is behind the development of the potential candidates for cancer vaccine, under the brand name SANTAVAC, that can be tuned against virtually any solid cancer. Our company is progressing the development of both prevention and therapeutic SANTAVAC vaccines.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month